12个月内达到狼疮低疾病活动度状态与重度活动性系统性红斑狼疮患者良好结局相关
纳入79例因重度活动性SLE起始泼尼松龙≥0.4 mg/kg/天诱导治疗的患者,按达到LLDAS时间分为≤6个月、6-12个月、>12个月及未达LLDAS组。6例(7.6%)在6个月内、41例(51.9%)在12个月内达到LLDAS,较短时间达标者更可能以≥50%时间处于LLDAS且累积泼尼松龙剂量更低,未观察到器官损伤累积差异。作者认为诱导治疗后12个月内达到LLDAS可能对重度活动性SLE患者有利。
要点
- 79例重度活动性SLE患者中仅6例(7.6%)6个月内、41例(51.9%)12个月内达到LLDAS。
- 达标时间较短者更可能以≥50%时间处于LLDAS,累积泼尼松龙剂量更低,损伤累积无差异。
- 超过12个月达标者血小板减少更常见,未达标者肾功能更低、起始泼尼松龙剂量及激素冲击比例更高。
核心结论
- 诱导治疗后12个月内达到LLDAS可能对重度活动性SLE患者有利,高危人群中LLDAS达标率低提示需要新的SLE治疗策略。
研究设计与样本
- 研究纳入79例因活动性狼疮(BILAG 2004指数A≥1或B≥2)或基于SELENA-SLEDAI判定的严重复发而起始泼尼松龙≥0.4 mg/kg/天治疗的患者,按达到LLDAS时间分为≤6个月、6-12个月、>12个月及未达LLDAS组,分析达标时间与复发、损伤累积及≥50%时间处于LLDAS的关联。
主要发现
- 平均SLEDAI为17,泼尼松龙起始剂量中位数0.95 mg/kg/天,平均观察期39.7个月。
- 6例(7.6%)在6个月内达到LLDAS,41例(51.9%)在12个月内达到LLDAS。
- 达到LLDAS时间较短的患者更可能以≥50%的时间处于LLDAS,且累积泼尼松龙剂量更低。
- 不同达标时间组间未观察到器官损伤累积的差异。
- 达到LLDAS需超过12个月者血小板减少患病率更高;未达LLDAS者较12个月内达标者肾功能更低、泼尼松龙起始剂量更高且接受激素冲击治疗更多。
关键数值与推荐
- LLDAS达标时间分组为≤6个月、6-12个月、>12个月及未达LLDAS。
- 6个月和12个月内LLDAS达标率分别为7.6%(6例)和51.9%(41例)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To demonstrate the significance of the time to attain lupus low disease activity state (LLDAS) after remission induction therapy in patients with severely active SLE. METHODS: We enrolled 79 patients starting prednisolone ≥0.4 mg/kg/day for active lupus with a BILAG 2004 index of A ≥ 1 or B ≥ 2, or for severe flare based on the Safety of Estrogens in Lupus Erythematosus National Assessment-SLE Disease Activity Index (SELENA-SLEDAI). The time to LLDAS attainment was divided into ≤6, 6-12 and >12 months and non-LLDAS; associations between the timing of LLDAS and flares, damage accrual and ≥50% LLDAS attainment were examined. RESULTS: The mean SLEDAI was 17; median starting dose of prednisolone, 0.95 mg/kg/day; and mean observational period, 39.7 months. Six (7.6%) and 41 (51.9%) patients achieved LLDAS within 6 and 12 months. Patients with a shorter time to LLDAS achievement were more likely to spend ≥50% of the time in LLDAS and had a lower cumulative prednisolone dose; no differences were observed in damage accrual. Patients requiring longer than 12 months to achieve LLDAS had a higher prevalence of thrombocytopenia and those with non-LLDAS had lower renal function and a higher starting dose of prednisolone and steroid pulse therapy than those who achieved LLDAS within 12 months. CONCLUSION: Achieving LLDAS within 12 months of induction therapy may be favourable in patients with severely active SLE. The low frequency of LLDAS attainment in high-risk populations highlights the need for a new strategy for SLE treatment.
引用
- Kikuchi J, Hanaoka H, Saito S, et al. Lupus low disease activity state within 12 months is associated with favourable outcomes in severely active systemic lupus erythematosus. Rheumatology (Oxford). 2022. PMID: 35015824. doi:10.1093/rheumatology/keac002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。